2010
DOI: 10.1016/j.jpainsymman.2009.09.017
|View full text |Cite
|
Sign up to set email alerts
|

Do the Trajectories of Dyspnea Differ in Prevalence and Intensity By Diagnosis at the End of Life? A Consecutive Cohort Study

Abstract: Prevalence of breathlessness increases rapidly at life's end, especially for people with primary lung cancer; the levels of breathlessness became close to those experienced by people with noncancer diagnoses despite symptom control measures.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

10
135
1
9

Year Published

2011
2011
2017
2017

Publication Types

Select...
6
3

Relationship

2
7

Authors

Journals

citations
Cited by 197 publications
(155 citation statements)
references
References 31 publications
10
135
1
9
Order By: Relevance
“…[2,3] Moreover, with many respiratory, cardiac, haematological, oncological and neuromuscular disorders, breathlessness is likely to worsen over time. [4] There are no symptomspecific medications to treat refractory dyspnoea registered with the major pharmaceutical regulatory bodies such as the Food and Drug Administration (FDA; USA), European Medicines Evaluation Agency (EMEA; Europe) or Therapeutic Goods Administration (TGA; Australia).…”
Section: Introductionmentioning
confidence: 99%
“…[2,3] Moreover, with many respiratory, cardiac, haematological, oncological and neuromuscular disorders, breathlessness is likely to worsen over time. [4] There are no symptomspecific medications to treat refractory dyspnoea registered with the major pharmaceutical regulatory bodies such as the Food and Drug Administration (FDA; USA), European Medicines Evaluation Agency (EMEA; Europe) or Therapeutic Goods Administration (TGA; Australia).…”
Section: Introductionmentioning
confidence: 99%
“…2,3 Across the population, the prevalence and intensity of breathlessness both increase as death approaches. 4,5 Level I evidence supports the use of morphine for reducing the subjective sensation of breathlessness. 1,6 More recently, these studies have been complemented by a phase IV study confirming that the net benefits are sustained over time without further dose increases 7 and identifying people whose breathlessness is most likely to respond to opioids.…”
mentioning
confidence: 99%
“…Die Prävalenz von Atemnot unterscheidet sich je nach der Grunderkrankung und nimmt mit nahendem Tod zu [10,20]. Die Prävalenz von Atemnot bei Tumorerkrankungen variiert zwischen 16-77 %, abhängig von der Tumorentität und der Art der Erhebung [10,20,29].…”
Section: Hintergrundunclassified
“…über 40 Jahre alt [31]. Basierend auf aktuellen Prävalenzangaben für die fortgeschrittene COPD (0,8 % im Alter ≥ 40 Jahre, GOLD Stadien III-IV [13]) oder den fortgeschrittenen Lungenkrebs (76 100, 5-Jahresprävalenz [27] ▶ Australien:50 % drei Monate vor Lebensende mit einem Anstieg auf 65 % in der letzten Lebenswoche [10]. In einer aktuellen multizentrischen Beobachtungsstudie über Patienten mit fortgeschrittenem Lungenkrebs in den USA (n = 450), Frankreich (n = 613) und Deutschland (n = 600) wurde jüngst eine besonders hohe Symptombelastung durch Atemnot (> 90 %) sowie ihr negativer Effekt auf die Lebensqualität dieser Patientengruppe beschrieben [18,19].…”
Section: Hintergrundunclassified